We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Healthcare ETFs Shine as Investors Rotate Out of Tech
Read MoreHide Full Article
The healthcare sector is one of the best-performing sectors this year. Over the past six months, healthcare is up about 24%, while technology is down about 6%, marking the widest divergence in performance in many years.
Many investors are moving money out of AI and technology and into defensive sectors and safer areas of the market. Healthcare has historically performed well during uncertain times, including in the run-up to the November midterm elections. Insurers and hospital operators rallied after Democrats won control of Congress.
Meanwhile, we have seen continued advances in healthcare, with new drug types and technologies emerging. In addition to the boom in GLP-1 medications, companies have announced successful clinical trials in cancer treatments and promising new cancer vaccines.
Healthcare companies have also been beating Wall Street's earnings expectations. Hospitals, insurers, and drugmakers are using AI to reduce paperwork, accelerate drug research, and operate more efficiently.
Biotech and genomics have done particularly well within the sector, as the FDA has signaled a more flexible approach to approving treatments for serious diseases. Many of these companies are leveraging AI models to design proteins, map single-cell gene activity, and conduct automated biological experiments.
Large pharmaceutical companies have plenty of cash and need new products to replace older drugs whose patents are expiring. They have been acquiring smaller, innovative biotech companies at a rapid pace to strengthen their product pipelines.
Biotech IPOs and secondary financings have also rebounded sharply, giving smaller firms fresh capital to fund clinical trials.
To learn more about these the State Street Health Care Select Sector SPDR ETF ((XLV - Free Report) ), iShares Genomics Immunology and Healthcare ETF ((IDNA - Free Report) ) and VanEck Biotech ETF ((BBH - Free Report) ), please watch the short video above.
Healthcare ETFs Shine as Investors Rotate Out of Tech
The healthcare sector is one of the best-performing sectors this year. Over the past six months, healthcare is up about 24%, while technology is down about 6%, marking the widest divergence in performance in many years.
Many investors are moving money out of AI and technology and into defensive sectors and safer areas of the market. Healthcare has historically performed well during uncertain times, including in the run-up to the November midterm elections. Insurers and hospital operators rallied after Democrats won control of Congress.
Meanwhile, we have seen continued advances in healthcare, with new drug types and technologies emerging. In addition to the boom in GLP-1 medications, companies have announced successful clinical trials in cancer treatments and promising new cancer vaccines.
Healthcare companies have also been beating Wall Street's earnings expectations. Hospitals, insurers, and drugmakers are using AI to reduce paperwork, accelerate drug research, and operate more efficiently.
Biotech and genomics have done particularly well within the sector, as the FDA has signaled a more flexible approach to approving treatments for serious diseases. Many of these companies are leveraging AI models to design proteins, map single-cell gene activity, and conduct automated biological experiments.
Large pharmaceutical companies have plenty of cash and need new products to replace older drugs whose patents are expiring. They have been acquiring smaller, innovative biotech companies at a rapid pace to strengthen their product pipelines.
Biotech IPOs and secondary financings have also rebounded sharply, giving smaller firms fresh capital to fund clinical trials.
To learn more about these the State Street Health Care Select Sector SPDR ETF ((XLV - Free Report) ), iShares Genomics Immunology and Healthcare ETF ((IDNA - Free Report) ) and VanEck Biotech ETF ((BBH - Free Report) ), please watch the short video above.